Urea, creatinine, and uric acid

Urea, creatinine, and uric acid are the primary nitrogenous waste products of human metabolism and serve as essential clinical biomarkers for evaluating renal function and metabolic health (StatPearls, NBK542265). Urea is produced in the liver through the urea cycle as a means to detoxify ammonia derived from protein catabolism (StatPearls, NBK513323). Creatinine is generated at a relatively constant rate from the breakdown of creatine phosphate in skeletal muscle, making its serum concentration a reliable proxy for the glomerular filtration rate (NIH, PubChem CID 588). Uric acid is the final metabolic product of purine degradation; its accumulation can lead to hyperuricemia, which is the underlying cause of gout and certain types of kidney stones (StatPearls, NBK459218). Although these molecules are not therapeutic targets in the sense of being receptors or enzymes, their levels are frequently monitored to assess the safety and efficacy of various pharmacological interventions. For instance, xanthine oxidase inhibitors like allopurinol are used to reduce uric acid production, while the clearance of urea and creatinine is a key metric in managing chronic kidney disease and drug-induced nephrotoxicity (PubMed, PMID: 29477145).

Other names

Nitrogenous waste productsRenal function markersNon-protein nitrogenous compoundsNPN compounds

These molecules are metabolic end-products and do not possess a mechanism of action as therapeutic targets. Pharmacological management focuses on inhibiting the enzymes responsible for their production (e.g., xanthine oxidase for uric acid) or modulating renal transporters (e.g., URAT1, OAT1) to increase their excretion (StatPearls, NBK459218; PubMed, PMID: 29477145).